Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Current as of December 10, 2023
Because AZT leaves the bloodstream quickly, patients must take the drug frequently to keep adequate amounts in their bodies. Probenecid and quinine may slow down the rate at which AZT leaves the body. Therefore, taking these drugs along with AZT may reduce the amount of AZT needed for treatment. In part I, four patients who are now receiving AZT at the usual dose take part in pharmacokinetic studies (how much of the drug enters the blood stream, what happens to the drug in the body, and how it leaves the body) of AZT defined after a dose while at steady state and then again after a new ste...
- Inclusion Criteria
- Patients must:
- Have symptomatic HIV infection.
- Be taking zidovudine (AZT), 100 or 200 mg, 5 or 6 x/day.
- History of Pneumocystis carinii pneumonia (PCP).
- Advanced AIDS related complex (ARC).
- HIV antibody positive with an absolute CD4 lymphocyte count of < 200 cells/mm3 before study entry.
- Exclusion Criteria
- Co-existing Condition:
- Patients with any of the following conditions are excluded:
- Glucose-6-phosphate dehydrogenase deficiency.
- Allergy to sulfa drugs, probenecid, or quinine.
- Concurrent Medication:
- - Other drugs that might influence the metabolism or renal excretion of zidovudine (AZT).
The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Baltimore, Maryland, United States
All reviews come from applied patients